Consequently, the combination of anti-VEGF or anti-VEGFR and anti-PD-1/PD-L1 suppresses a potential mechanism of immunologic tolerance by inhibition of VEGF and reduction of FasL levels, hence promoting CD8+ tumor infiltration and the responsiveness of HCC to checkpoint inhibitors. The gene discussed is FASLG; the disease is hepatocellular carcinoma.